Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

Clinical Trial ID NCT00334282

PubWeight™ 31.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00334282

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.	J Clin Oncol	2010	13.03
2	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.	Lancet Oncol	2012	4.58
3	A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.	Eur J Cancer	2013	2.51
4	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.	Angiogenesis	2014	2.07
5	Estimation of renal cell carcinoma treatment effects from disease progression modeling.	Clin Pharmacol Ther	2012	1.55
6	Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.	Br J Cancer	2010	1.25
7	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.	Br J Cancer	2015	0.93
8	Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.	Br J Cancer	2014	0.92
9	Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.	J Hepatol	2011	0.86
10	Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.	Cancer Chemother Pharmacol	2013	0.83
11	Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.	Int J Cancer	2016	0.79
12	Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.	Curr Oncol	2016	0.77
13	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?	Eur J Cancer	2015	0.76
14	Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.	Br J Cancer	2016	0.76
15	Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs.	Oncotarget	2016	0.75